At the conclusion of this session participants should be able to:

• describe the recent insights in the molecular and cellular events that underlie pathologic bone remodeling in axial spondylarthritis and psoriatic arthritis
• develop a more comprehensive approach to the treatment of axial spondylarthritis and psoriatic arthritis that includes attention to metabolic and cardiovascular risk factors based on data
• discuss the rapidly expanding treatment pipeline in axial spondylarthritis and psoriatic arthritis and how these new agents will impact current treatment algorithms

At the conclusion of this session participants should be able to:

• explain the clinical importance of different forms of lung fibrosis
• discuss the concept of interstitial lung disease in the setting of an undifferentiated connective tissue disease
• identify the management issues for patients with interstitial lung disease in the setting for connective tissue disease

At the conclusion of this session participants should be able to:

• identify general mechanisms of signal transduction
• explain how signal transduction plays a role in the pathogenesis of rheumatic disease
• learn the risks and benefits of blocking signaling pathways in rheumatic disease

At the conclusion of this session participants should be able to:

• detail the key clinical, laboratory, and pathologic features of Sjogren's syndrome
• detail the steps required to establish a diagnosis of Sjogren's syndrome
• detail the therapeutic interventions currently available and under investigation for Sjogren's syndrome

At the conclusion of this session participants should be able to:

• recognize the importance of lung biopsy patterns
• describe the essential mechanisms for progression of pulmonary fibrosis
• discuss emerging therapeutic strategies for targeting pulmonary fibrosis

At the conclusion of this session participants should be able to:

• identify the genetic and environmental influences that contribute to susceptibility and severity of rheumatoid arthritis
• explain how innate immunity and autoreactivity to citrullinated peptides can initiate synovitis
• conceive how the initiating events lead to chronic arthritis and joint destruction in rheumatoid arthritis

At the conclusion of this session participants should be able to:

• discuss the rationale for kinase inhibitors in rheumatoid arthritis
• discuss the efficacy of kinase inhibitors in rheumatoid arthritis
• discuss the toxicity of kinase inhibitors in rheumatoid arthritis

At the conclusion of this session participants should be able to:

• develop a methodology for clinically evaluating patients with ANCA-associated vasculitis [granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis]
• discuss the findings and implications of recent clinical trials for small vessel vasculitis
• explain the current standard of care treatment protocols for patients with ANCA-associated vasculitis
• discuss the current areas of clinical investigation of ANCA-associated vasculitis

At the conclusion of this session participants should be able to:

• identify the methodologic principles of ANCA-testing and how they affect the clinical interpretation of test results
• recognize limitations and potential diagnostic pitfalls of ANCA-test
• list the prognostic implications of MPO-ANCA versus PR3-ANCA
• assess the clinical utility of serial ANCA testing in the management of vasculitis patients

At the conclusion of this session participants should be able to:

• identify new medications that have FDA approval for use in juvenile idiopathic arthritis
• assess new studies of early aggressive therapy for poly-juvenile idiopathic arthritis
• plan treatment for children with resistant systemic juvenile idiopathic arthritis

At the conclusion of this session participants should be able to:

• review the clinical presentations of rheumatologic disorders that may be associated with malignancy
• review the literature regarding the management and clinical outcomes for these conditions
• discuss the possible underlying mechanisms for paraneoplastic clinical events

At the conclusion of this session participants should be able to:

• explain which children with juvenile idiopathic arthritis are most at risk for uveitis
• differentiate malignancy from juvenile idiopathic arthritis
• identify treatments for linear scleroderma

At the conclusion of this session participants should be able to:

• provide an overview of the presentations of rheumatic diseases with neurologic overlap
• describe the pathogenesis of these conditions
• review how to diagnoses and manage these disorders

At the conclusion of this session participants should be able to:

• describe the challenges of engineering biologically and biomechanically functional joint tissue
• summarize the role of currently available tissue engineering approaches in joint disease
• discuss strategies currently under development for repairing and replacing critical joint tissues

At the conclusion of this session participants should be able to:

• provide an algorithm for diagnosis of early systemic sclerosis
• discuss the revised ACR/EULAR classification of systemic sclerosis
• evidence-based treatment of patients with early systemic sclerosis

At the conclusion of this session participants should be able to:

• discuss current therapeutic approaches to symptomatic osteoarthritis
• define the relative roles of symptom modification and structure modification in osteoarthritis disease progression
• summarize biomechanical strategies to modify osteoarthritis disease progression

At the conclusion of this session participants should be able to:

• review the role of type I interferon in anti-viral host defense
• describe data supporting a pathogenic role for interferon in the pathogenesis of lupus
• describe approaches to regulate interferon production and function in lupus therapy

At the conclusion of this session participants should be able to:

• review current technologies useful for studies of disease pathogenesis
• describe new insights into lupus disease provided by gene expression and proteomic analysis
• describe approaches to development of molecular tools for patient management

At the conclusion of this session participants should be able to:

• review the current state-of-the-art in the treatment of lupus
• share the results of clinical trials in patients with lupus nephritis
• provide new insights into the design and interpretation of lupus trials

At the conclusion of this session participants should be able to:

• discuss evidence-based data on the immunosuppressive therapies for systemic sclerosis and related fibrotic complications
• discuss evidence-based data on the therapeutic options available for treatment of vascular complications

At the conclusion of this session participants should be able to:

• identify and define components of balance (compromises and changes for rheumatoid arthritis)
• explain the role of properly matched equipment to compliment comfort and performance
• discuss conditioning for altitude athletics and the fun factor